CompletedPhase 2/3

Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm

South Korea234 participantsStarted 2016-10

Plain-language summary

The purpose of this study is to evaluate the Efficacy and Safety of NABOTA in treatment of essential blepharospasm

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male of female of at least 18 years old * Grade 2\~4 in Scott's scale

The change from baseline in Scott's Scale Score

Timeframe: At 4 weeks

NCT IDNCT02947815

SponsorDaewoong Pharmaceutical Co. LTD.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-01